Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A phase II, open-label, randomized, multicentre study to evaluate the feasibility of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine co-administered with Prevenar compared with Pediacel co-administered with Menjugate and Prevenar, when given in healthy infants as a three-dose primary vaccination course at 2, 3 and 4 months of age and to evaluate Menitorix given to these children as a booster dose at 12 months of age https://kusajili.com:443/Trial/K1OO6h6m8UCvFGlskphVpQ%24a-phase-ii-open-label-randomized-multicentre-study-to-evaluate-the-feasibility-of-gsk-biologicals-dtpa-ipvhib-menc-tt-vaccine-c
I have read and accept the terms of use of the site and the Privacy Policy
Send your message